Zobrazeno 1 - 10
of 18
pro vyhledávání: '"F P J G, Lafeber"'
Autor:
M. S. Jurgens, M. Safy-Khan, M. J. H. de Hair, J. W. J. Bijlsma, P. M. J. Welsing, J. Tekstra, F. P. J. G. Lafeber, E. H. Sasso, J. W. G. Jacobs, on behalf of the Society for Rheumatology research Utrecht
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-9 (2020)
Abstract Objectives The CAMERA-II trial compared two tight-control, treat-to-target strategies, initiating methotrexate with prednisone (MTX+pred) or MTX with placebo (MTX+plac), in early RA-patients. The multi-biomarker disease activity (MBDA) blood
Externí odkaz:
https://doaj.org/article/56fda2b3974a492dbf353dccefa2737e
Autor:
N. J. Besselink, A. A. A. Westgeest, R. Klaasen, M. Gamala, J. M. van Woerkom, J. Tekstra, M. M. A. Verhoeven, W. E. Van Spil, F. P. J. G. Lafeber, A. C. A. Marijnissen, J. M. Van Laar, J. W. G. Jacobs
Publikováno v:
Trials, Vol 20, Iss 1, Pp 1-10 (2019)
Abstract Background Assessment of disease activity is a critical component of tight-control, treat-to-target treatment strategies of rheumatoid arthritis (RA). Recently, the HandScan has been validated as a novel method for objectively assessing RA d
Externí odkaz:
https://doaj.org/article/7aeddec0d7b940cfa2f67aec32d6d6ac
Autor:
E M van Helvoort, J Popov-Celeketic, N Eijkelkamp, K Coeleveld, M A Tryfonidou, C D Wijne, C E Hack, F P J G Lafeber, S C Mastbergen
Publikováno v:
PLoS ONE, Vol 14, Iss 7, p e0219587 (2019)
ObjectiveAn ideal disease modifying osteoarthritis drug (DMOAD) has chondroprotective, anti-inflammatory, and analgesic effects. This study describes the production and characterization of a canine IL4-10 fusion protein (IL4-10 FP) and evaluates its
Externí odkaz:
https://doaj.org/article/1b11265c96bc4c6c89a1c1f3cdda314d
Autor:
N J Besselink, J W G Jacobs, A A A Westgeest, P van der Meijde, P M J Welsing, A C A Marijnissen, F P J G Lafeber, W E Van Spil
Publikováno v:
PLoS ONE, Vol 14, Iss 2, p e0209761 (2019)
ObjectiveTo determine whether optical spectral transmission (OST) can be used to assess synovitis in hand and wrist joints of patients with hand osteoarthritis (OA).DesignHand and wrist joints of 47 primary hand OA patients with at least one clinical
Externí odkaz:
https://doaj.org/article/dffbf9679c254de4b4fdea9288697aeb
Autor:
H M de Visser, S C Mastbergen, S Ravipati, P M J Welsing, F C Pinto, F P J G Lafeber, V Chapman, D A Barrett, H Weinans
Publikováno v:
PLoS ONE, Vol 13, Iss 4, p e0196308 (2018)
Bioactive oxidised lipids (oxylipins) are important signalling mediators, capable of modulating the inflammatory state of the joint and anticipated to be of importance in joint homeostasis and status of osteoarthritis. The aim of this study was to qu
Externí odkaz:
https://doaj.org/article/aa5199d6bcdd44779840e05f3420ed20
Autor:
S C Nair, P M J Welsing, I Y K Choi, J Roth, D Holzinger, J W J Bijlsma, J M van Laar, D M Gerlag, F P J G Lafeber, P P Tak
Publikováno v:
PLoS ONE, Vol 11, Iss 3, p e0152362 (2016)
Measurement of MRP8/14 serum levels has shown potential in predicting clinical response to different biological agents in rheumatoid arthritis (RA). We aimed to develop a treatment algorithm based on a prediction score using MRP8/14 measurements and
Externí odkaz:
https://doaj.org/article/244baf6716a743a3939bbbc47b15a0cc
Autor:
J A D van der Woude, S C Nair, R J H Custers, J M van Laar, N O Kuchuck, F P J G Lafeber, P M J Welsing
Publikováno v:
PLoS ONE, Vol 11, Iss 5, p e0155524 (2016)
OBJECTIVE:In end-stage knee osteoarthritis the treatment of choice is total knee arthroplasty (TKA). An alternative treatment is knee joint distraction (KJD), suggested to postpone TKA. Several studies reported significant and prolonged clinical impr
Externí odkaz:
https://doaj.org/article/a34c44bcba404f56a4ef1d4035fd9d24
Autor:
E D P, van Bergen, M, Monnikhof, F P J G, Lafeber, R E G, Schutgens, S C, Mastbergen, L F D, van Vulpen
Publikováno v:
Blood Reviews. 56:100987
(Non-)selective non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used for musculoskeletal related pain. These cheap and easily accessible drugs may be of great value for hemophilia patients in developing countries and countries with a high
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c77a070f9ee5f7893ba6f4eb8ef01a01
https://doi.org/10.1016/j.blre.2022.100987
https://doi.org/10.1016/j.blre.2022.100987
Publikováno v:
Arthritisrheumatology (Hoboken, N.J.). 67(3)
To investigate whether the potential of abatacept to inhibit vigorous CD1c myeloid dendritic cell (MDC)-driven activation of naive and memory CD4 T cells is abrogated in the presence of T cell-activating cytokines.CD4 T cell subsets (naive [Tn], cent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4d699b8b6e04e4d325e8789007b374cb
https://pubmed.ncbi.nlm.nih.gov/25469671
https://pubmed.ncbi.nlm.nih.gov/25469671
Autor:
J.M. van Laar, J. Tekstra, Y. K. O. Teng, Johannes W. J. Bijlsma, F. P. J. G. Lafeber, F. C. Breedveld
Publikováno v:
Annals of the Rheumatic Diseases, 68(6), 1075-1077. BMJ PUBLISHING GROUP
Rituximab, an anti-CD20 monoclonal antibody, has been approved for treatment in patients with rheumatoid arthritis (RA) who have failed treatment with tumour necrosis factor (TNF) blocking agents.1 Previous studies have demonstrated its safety, effic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f1a311d9f5b8447b09444a774dabc84
https://hdl.handle.net/11370/cab61c6a-b27a-4f27-a43f-6dad6588eeca
https://hdl.handle.net/11370/cab61c6a-b27a-4f27-a43f-6dad6588eeca